Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma
- 1 October 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (28) , 4572-4578
- https://doi.org/10.1200/jco.2007.15.5655
Abstract
Purpose Sorafenib is an antiangiogenic agent with activity in renal cancer. We conducted a randomized trial to investigate dynamic contrast magnetic resonance imaging (DCE-MRI) as a pharmacodynamic...Keywords
This publication has 30 references indexed in Scilit:
- Multiple reference tissue method for contrast agent arterial input function estimationMagnetic Resonance in Medicine, 2007
- MRI of tumor angiogenesisJournal of Magnetic Resonance Imaging, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?European Journal Of Cancer, 2006
- A unified magnetic resonance imaging pharmacokinetic theory: Intravascular and extracellular contrast reagentsMagnetic Resonance in Medicine, 2005
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I StudyJournal of Clinical Oncology, 2005
- Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursEuropean Journal Of Cancer, 2005
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000